Phase 1 Autoimmune Hemolytic Anemia Clinical Trials
4 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–4 of 4 trials
Recruiting
Phase 1
Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases
Relapsed/Refractory Systemic Lupus ErythematosusRelapsed/Refractory Systemic SclerosisRelapsed/Refractory Idiopathic Inflammatory Myopathies+3 more
Beijing Boren Hospital12 enrolled1 locationNCT07361094
Recruiting
Phase 1Phase 2
A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia
Autoimmune Hemolytic AnemiaEvans SyndromeAutoimmune Cytopenia+1 more
Keymed Biosciences Co.Ltd158 enrolled3 locationsNCT07175493
Recruiting
Phase 1
OM336 in Autoimmune Cytopenias
ITP - Immune ThrombocytopeniaAIHA - Warm Autoimmune Hemolytic AnemiaAIHA - Cold Autoimmune Hemolytic Anemia
Ouro Medicines32 enrolled3 locationsNCT07083960
Recruiting
Phase 1
CAR T-cell Therapy Targeting CD19 and BCMA in Patients with AIHA Who Have Failed ≥3 Lines of Therapy.
Autoimmune Hemolytic AnemiaCD19/BCMA CAR T-cellsUniversal Allogeneic CAR T-cells
Institute of Hematology & Blood Diseases Hospital, China15 enrolled1 locationNCT06733610